HIV News Alert

CDC has released Interim Guidance for Prevention and Treatment of Monkeypox in Persons with HIV Infection. On August 4, 2022, the United States declared monkeypox a public health emergency. The current outbreak disproportionately affects gay, bisexual, and other men who have sex with men (MSM). MSM are also disproportionately affected by HIV. A recent study provides insights into…

The Panel on Opportunistic Infections in Adults and Adolescents (the Panel) updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below:  Monkeypox Added a brief statement about monkeypox with a link to information from the Centers for Disease Control and Prevention (CDC). Information…

Monday, August 01, 2022: CHICAGO—Governor Pritzker issued a proclamation today declaring the monkeypox virus a public health emergency and declaring the state of Illinois a disaster area regarding the disease. The declaration, which applies to the entire state, will allow the Illinois Department of Public Health (IDPH) to utilize resources for coordinating logistics across state…

As the 2022 monkeypox outbreak continues to accelerate, the Centers for Disease Control and Prevention recently released a “Dear Colleague Letter” for health care providers and care team members highlighting the importance of addressing pain control in persons with monkeypox. To view the letter (PDF) click here or view below.

June 10, 2022: Governor JB Pritzker of Illinois signed HB4430 and HB5549 into law today, removing barriers to access for HIV and AIDS care and prevention. HB4430 allows pharmacists to dispense both pre- and post-exposure prophylaxis drugs (PrEP and PEP) without a prior referral from a doctor. HB5549 ensures funding from the African American HIV/AIDS…

The 2022 National Drug Control Strategy was released on April 21, 2022. Over the course of a year, it was developed through requests for written consultations from more than 2,000 external stakeholders, including the entirety of the U.S. Congress; all 50 Governors; and hundreds of advocates representing law enforcement, public health, and Tribal communities. This new Strategy…

April 12, 2022: The Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV (the Panel) has reviewed the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Key updates are summarized below: The U.S. Food and Drug Administration (FDA) recently approved long-acting injectable cabotegravir and rilpivirine (Cabenuva) for use in children and…

February 7, 2022:  The COVID-19 Treatment Guidelines Panel (the Panel) has published a revised version of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. The Panel periodically publishes statements that provide up-to-date guidance for clinicians on various aspects of COVID-19 treatment. During this update, the information and recommendations from several recently published statements were incorporated into the…

February 17, 2022: The Panel updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Highlights from the updated section are summarized below:  Mycobacterium tuberculosis Updated references and rationales. Updated drug–drug interactions. Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy. Clarified that, for the…

On December 10, 2021, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every…